Sandbox: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 4: | Line 4: | ||
by Gina Kolata, ''New York Times'', 17 November 2013 | by Gina Kolata, ''New York Times'', 17 November 2013 | ||
The article links to | The article links to a graphic summarizing the findings | ||
[[File:EstimatingRisk.png | 800 px ]] | [[File:EstimatingRisk.png | 800 px ]] | ||
Revision as of 21:01, 18 November 2013
Flaws in cholesterol risk calculator?
Risk calculator for cholesterol appears flawed
by Gina Kolata, New York Times, 17 November 2013
The article links to a graphic summarizing the findings
For commentary on a related story, see the post The Economics & Politics of Drugs for Mild Hypertension from HealthNewsReview.org (4 November 2013), which begins
The Cochrane Collaboration’s Hypertension Group published a systematic review of drug treatment for mild hypertension in August 2012 showing no evidence that drugs benefit patients while about 11% have side effects severe enough to stop treatment. As coauthor of that review, I will comment on the economics, politics, regulatory intrigue, financial conflicts, and subsequent media coverage involved.
Submitted by Paul Alper